2020 Volume 8 Issue 1 Pages 10-11
FSCJ conducted a risk assessment of fluxametamide (CAS No. 928783-29-3), an isoxazoline insecticide, based on results from various studies. The data used in the assessment include the fate in animals, fate in plants, residues in crops, subacute toxicity, subacute neurotoxicity, chronic toxicity, combined chronic toxicity/carcinogenicity, carcinogenicity, two-generation reproductive toxicity, developmental toxicity, and genotoxicity. Alveolar macrophage accumulation, vacuolated epithelial cells in the small intestine, and hepatocellular vacuolation are observed in various toxicity studies. Increased incidences of thyroid follicular cell adenoma in male rats and of hepatocellular adenoma in male mice were observed in carcinogenicity studies. However, a genotoxic mechanism was unlikely to be involved in the tumor increases. FSCJ specified an acceptable daily intake (ADI) of 0.0085 mg/kg bw per day, applying a safety factor of 100 to the NOAEL, 0.85 mg/kg bw per day, that was derived from the two-year combined chronic toxicity/carcinogenicity study in rats.